15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          REVEL demonstrated that ramucirumab+docetaxel (RAM+DTX) improved overall survival, progression-free survival, and objective response rate in patients with advanced/metastatic non-small cell lung cancer with progression after platinum-based chemotherapy. This analysis examined quality of life (QoL) as assessed by the Lung Cancer Symptom Scale (LCSS) and clinician-reported functional status.

          Related collections

          Author and article information

          Journal
          Lung Cancer
          Lung cancer (Amsterdam, Netherlands)
          1872-8332
          0169-5002
          Mar 2016
          : 93
          Affiliations
          [1 ] Léon-Bérard Cancer Centre, Lyon, France. Electronic address: maurice.perol@lyon.unicancer.fr.
          [2 ] Institute of Oncology Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania. Electronic address: tudor@iocn.ro.
          [3 ] Instituto Nacional de Cancerologia, Mexico City, Mexico. Electronic address: cogar@servidor.unam.mx.
          [4 ] Tata Memorial Hospital, Mumbai, India. Electronic address: kprabhash1@gmail.com.
          [5 ] Oncology Unite GPP, Sotiria General Hospital, Athens, Greece. Electronic address: ksyrigos@med.uoa.gr.
          [6 ] Ege University School of Medicine, Izmir, Turkey. Electronic address: tuncaygoksel@gmail.com.
          [7 ] Samsung Medical Center, Seoul, South Korea. Electronic address: keunchil.park@samsung.com.
          [8 ] Centro de Investigaciones Clínicas, Clínica Viedma, S.A., Argentina. Electronic address: kowar@rnonline.com.ar.
          [9 ] Wojewodzkie Centrum Onkologii, Gdansk, Poland. Electronic address: joanna.pikiel@post.pl.
          [10 ] Charing Cross Hospital, London, UK. Electronic address: Conrad.lewanski@imperial.nhs.uk.
          [11 ] Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany. Electronic address: michael.thomas@med.uni-heidelberg.de.
          [12 ] Cancer Center of Kansas, Wichita, KS, USA. Electronic address: shaker.dakhil@cancercenterofkansas.com.
          [13 ] Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea. Electronic address: kjhang@yuhs.ac.
          [14 ] City Clinical Oncology Dispensary, St. Petersburg, Russia. Electronic address: nkaraseva06@mail.ru.
          [15 ] Eli Lilly and Company, Bridgewater, NJ, USA. Electronic address: sergey.yurasov@imclone.com.
          [16 ] Eli Lilly and Company, Indianapolis, IN, USA; LungenClinic Grosshansdorf, German Center for Lung Research, Grosshansdorf, Germany. Electronic address: zimmermann_annamaria_hayden@lilly.com.
          [17 ] LungenClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany. Electronic address: pablo.lee@imclone.com.
          [18 ] Eli Lilly and Company, Indianapolis, IN, USA; LungenClinic Grosshansdorf, German Center for Lung Research, Grosshansdorf, Germany.
          [19 ] LungenClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany. Electronic address: M.Reck@lungenclinic.de.
          [20 ] Istituto Toscano Tumori, Livorno, Italy. Electronic address: f.cappuzzo@googlemail.com.
          [21 ] David Geffen School of Medicine at UCLA/Translational Research in Oncology-US Network, Los Angeles, CA, USA. Electronic address: egaron@mednet.ucla.edu.
          Article
          S0169-5002(16)30007-1
          10.1016/j.lungcan.2016.01.007
          26898621
          Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

          Comments

          Comment on this article